Does MassHealth Cover Wegovy or Zepbound? The July 3, 2026 Cutoff and What Remains

No. Wegovy and Zepbound have been off the MassHealth list for weight loss since July 3, 2026, when a state regulation barred payment for drugs prescribed for obesity or overweight, on every MassHealth plan.^[2][3] As of November 2026 Wegovy remains the preferred drug for three other uses (heart-risk reduction, sleep apnea and the liver disease MASH), with prior authorization. Requests for people under 21 still get a medical necessity review under federal child-health rules.^[1][4]

What changed at MassHealth in July 2026?

Pharmacy Facts 271, in its corrected version, set the date at July 3, 2026 and listed the affected drugs.^[1] The regulation that followed, 130 CMR 406.413(B)(7), is one sentence and bars payment for any drug used for obesity or overweight.^[2] Three details make it broader than many states’ cutoffs.

• Older pills went too. The list includes phentermine, benzphetamine, diethylpropion, phendimetrazine, orlistat and phentermine-topiramate, along with Saxenda, Wegovy and Zepbound.^[3] Pennsylvania’s cutoff, by contrast, kept phentermine available.
• Off-label use is out. Any drug used off-label for weight loss cannot be paid for, so a diabetes GLP-1 written for weight does not get around the rule.^[1][4]
• Every plan is included. The change applies in fee-for-service, managed care organizations, accountable care partnership plans, primary care ACOs and the PCC Plan, as well as PACE, Senior Care Options and One Care.^[3]

States may exclude weight-loss drugs under federal Medicaid law, so this was a choice open to Massachusetts.^[13] Prior authorizations filed before February 17, 2026 ended on July 2, 2026 whatever they were for, so members using a drug for a still-covered reason had to file again.^[1]

How did MassHealth get here?

The cutoff came at the end of a two-and-a-half-year run in which coverage kept narrowing.

When will MassHealth still pay for Wegovy or Zepbound?

Three adult uses remain, each with prior authorization for members 18 and older. The Drug List criteria, last updated in October 2026, set the thresholds below, and each request needs medical records, not just a diagnosis code.^[16] For the sleep apnea route, Wegovy is not approved for members with type 2 diabetes, who are steered to a diabetes GLP-1 instead.^[16][4]

Zepbound’s position is the unusual part. MassHealth’s bulletins require a Wegovy trial before Zepbound, and the May 2026 e-letter says this applies to all patients continuing Zepbound past July 2.^[3][4] Yet Zepbound is the one with the FDA-approved sleep apnea use.^[12] The current criteria go further: Zepbound needs six months of semaglutide that did not bring the apnea index down enough (or a reaction or reason not to take it), plus a failed trial of at least three months on CPAP or a similar breathing device in the past year.^[16] Members who held a Zepbound approval for a covered use running past that date had it replaced with a Wegovy approval for the remaining time, and needed a new prescription.^[3] On the Drug List index, Wegovy carries the preferred-drug mark and Zepbound does not, and both require prior authorization.^[8][9]

Members of PACE, Senior Care Options and One Care are told to seek these uses through Medicare.^[3] If you have both programs and use the Medicare GLP-1 Bridge, MassHealth will not pay the $50 monthly copay; you owe it yourself.^[2]

Does MassHealth still cover Ozempic and Mounjaro for diabetes?

Yes. The cutoff does not touch diabetes. Ozempic injection, Trulicity, Victoza and Mounjaro were the preferred drugs in the March 2026 bulletin, and claims generally pay at the pharmacy when a diabetes diagnosis is on file and the claim is within quantity limits.^[1] Rybelsus, Bydureon BCise and exenatide were non-preferred then, but on October 1, 2026 Rybelsus and the new Ozempic tablet joined the preferred list, still with prior authorization.^[1][17] People who were on Wegovy or Zepbound and also have diabetes or prediabetes need a new prescription for a diabetes drug.^[4]

Prediabetes is the next thing to change. MassHealth covers some GLP-1s off-label for it, and on January 4, 2027 members stable on one lose their exemption from the metformin trial. Trulicity and Victoza can process without prior authorization if there are recent metformin or GLP-1 claims, while Mounjaro and semaglutide products will need it.^[7] The bulletin says diabetes coverage is unaffected.^[7]

How do you appeal a MassHealth denial?

Check the reason on the notice first. A denial for “obesity” runs into a regulation, while a denial over missing sleep study results or a fibrosis stage is a records problem you can fix and refile.^[1][2] The deadlines come from the MassHealth fair hearing rules, and the notice you received controls if it differs.

• MassHealth notices. The Board of Hearings must receive your request within 60 days after you receive written notice. Receipt is presumed on the fifth day after mailing.^[10] This window was extended from 30 days, so older forms and articles may show the wrong number.^[11]
• Managed care plans. Finish the plan’s internal appeal first. You then have 120 days after receiving its final decision to go to the Board of Hearings.^[10]

Federal rules that govern how a Medicaid managed care plan handles these drugs apply here as well.

What are the options if MassHealth stopped paying?

If your health history fits one of the remaining uses, ask your prescriber whether a new request is justified. Otherwise the choice is paying yourself. Lilly’s savings card for insured patients excludes anyone enrolled in Medicaid.^[14] Self-pay prices as of the figures we track are $349 a month for most Wegovy pen doses from Novo Nordisk, and $299 at the starting dose, $399 at 5 mg and $449 at 7.5 mg and up for Lilly’s Zepbound KwikPen or vial, when each refill comes within 45 days.^[14][15] Read each offer’s terms for government-program limits first. Phentermine is off the MassHealth list for weight loss too, so anyone still using it pays the generic cash price. Our comparison of the cheapest GLP-1 routes without insurance sets out the rest.